PubMed:23811795 / 855-1175 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T6","span":{"begin":0,"end":320},"obj":"Sentence"},{"id":"T6","span":{"begin":0,"end":320},"obj":"Sentence"},{"id":"T6","span":{"begin":0,"end":320},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T11","span":{"begin":314,"end":319},"obj":"FMAID:68646"},{"id":"_T12","span":{"begin":314,"end":319},"obj":"FMAID:169002"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"uniprot-human","denotations":[{"id":"T14","span":{"begin":55,"end":59},"obj":"http://www.uniprot.org/uniprot/Q16512"},{"id":"T15","span":{"begin":91,"end":95},"obj":"http://www.uniprot.org/uniprot/Q16512"},{"id":"T16","span":{"begin":154,"end":158},"obj":"http://www.uniprot.org/uniprot/Q16512"},{"id":"T23","span":{"begin":55,"end":59},"obj":"http://www.uniprot.org/uniprot/Q13153"},{"id":"T24","span":{"begin":91,"end":95},"obj":"http://www.uniprot.org/uniprot/Q13153"},{"id":"T25","span":{"begin":154,"end":158},"obj":"http://www.uniprot.org/uniprot/Q13153"},{"id":"T30","span":{"begin":31,"end":53},"obj":"http://www.uniprot.org/uniprot/Q13153"},{"id":"T34","span":{"begin":31,"end":34},"obj":"http://www.uniprot.org/uniprot/P38936"},{"id":"T35","span":{"begin":31,"end":51},"obj":"http://www.uniprot.org/uniprot/Q7Z2E4"},{"id":"T36","span":{"begin":31,"end":51},"obj":"http://www.uniprot.org/uniprot/Q9P286"},{"id":"T37","span":{"begin":31,"end":51},"obj":"http://www.uniprot.org/uniprot/O96013"},{"id":"T38","span":{"begin":31,"end":51},"obj":"http://www.uniprot.org/uniprot/Q9NQU5"},{"id":"T39","span":{"begin":31,"end":51},"obj":"http://www.uniprot.org/uniprot/Q13177"},{"id":"T40","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/Q02750"},{"id":"T41","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/P28482"},{"id":"T42","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/P45985"},{"id":"T43","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/Q07912"},{"id":"T44","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/P50613"},{"id":"T45","span":{"begin":35,"end":53},"obj":"http://www.uniprot.org/uniprot/Q15599"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"uniprot-mouse","denotations":[{"id":"T4","span":{"begin":31,"end":34},"obj":"http://www.uniprot.org/uniprot/P63028"},{"id":"T5","span":{"begin":31,"end":34},"obj":"http://www.uniprot.org/uniprot/Q62092"},{"id":"T6","span":{"begin":31,"end":34},"obj":"http://www.uniprot.org/uniprot/P39689"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T6","span":{"begin":314,"end":319},"obj":"http://purl.bioontology.org/ontology/STY/T025"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"GO-BP","denotations":[{"id":"T5","span":{"begin":263,"end":270},"obj":"http://purl.obolibrary.org/obo/GO_0043276"},{"id":"T31","span":{"begin":35,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0033674"},{"id":"T32","span":{"begin":206,"end":222},"obj":"http://purl.obolibrary.org/obo/GO_0033674"},{"id":"T33","span":{"begin":35,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0016301"},{"id":"T34","span":{"begin":206,"end":222},"obj":"http://purl.obolibrary.org/obo/GO_0016301"},{"id":"T35","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0050254"},{"id":"T36","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0052835"},{"id":"T37","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0004707"},{"id":"T38","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0004715"},{"id":"T39","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0019140"},{"id":"T40","span":{"begin":35,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0047944"},{"id":"T41","span":{"begin":206,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0004860"},{"id":"T42","span":{"begin":206,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0008384"},{"id":"T43","span":{"begin":206,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0007249"},{"id":"T44","span":{"begin":206,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0019210"},{"id":"T45","span":{"begin":216,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"GO-CC","denotations":[{"id":"T3","span":{"begin":314,"end":319},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"Allie","denotations":[{"id":"SS1_23811795_5_0","span":{"begin":31,"end":53},"obj":"expanded"},{"id":"SS2_23811795_5_0","span":{"begin":55,"end":59},"obj":"abbr"}],"relations":[{"id":"AE1_23811795_5_0","pred":"abbreviatedTo","subj":"SS1_23811795_5_0","obj":"SS2_23811795_5_0"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"PubmedHPO","denotations":[{"id":"T3","span":{"begin":142,"end":146},"obj":"HP_0000365"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}

{"project":"mondo_disease","denotations":[{"id":"T7","span":{"begin":305,"end":313},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"}],"text":"Mgat5 overexpression increased p21-activated kinase 1 (PAK1) expression and shRNA-mediated PAK1 knockdown and kinase inactivation with kinase dead mutant PAK1 K299R coexpression or allosteric inhibitor P21-activated kinase inhibitor III (IPA3) treatment reversed anoikis resistance in Mgat5-overexpressed hepatoma cells."}